Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
ANB033
product2 mentionslast seen Oct 15, 2026
CD122 antagonist investigational therapy designed to inhibit signaling of IL-15 and IL-2 on immune cells.
Relationships 5
- ANB033applies toceliac disease treatment99% confidence2 sources
- ANB033applies toeosinophilic esophagitis treatment99% confidence2 sources
- First Tracks Biotherapeutics, Inc.developsANB03399% confidence2 sources
- ANB033implementsCD122 antagonist94% confidence1 source
- U.S. Food and Drug AdministrationapprovesANB03392% confidence1 source
Relationship
ANB033applies toeosinophilic esophagitis treatment
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 15, 2026First Tracks Biotherapeutics, Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 3.02: Unregistered Sales of Equity Securities; Item 7.01: Regulation FD Disclosure; Item 9.01: Financial Statements and Exhibits
ANB033, a CD122 antagonist in development for celiac disease and eosinophilic esophagitis
- filingSEC EDGAROct 13, 2026First Tracks Biotherapeutics, Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
A Phase 1b cohort in eosinophilic esophagitis (EoE) is enrolling 50 patients